Laboratory and instrumental diagnostics of viral pneumonia (review)
Heading: Internal Diseases Article type: Review
Authors: Tyapkina D.A., Boroday А.А., Tyapayeva A.R., Semenova O.N., Naumova E.A.
Organization: Saratov State Medical University
The review analyzes the published data on laboratory and instrumental diagnostics of viral pneumonia. To search for articles, we used the PubMed database and eLIBRARY RU, as well as archives of the journals "Clinical Microbiology and antimicrobial chemotherapy", "Pulmonology", "Medical education today", "Complex problems of cardiovascular diseases", "Archives of internal medicine", "Kremlin medicine. Clinical Bulletin" and others. The literature review uses 44 sources of literature, articles published in the period from 2004 to 2020. Recently, in connection with the coronavirus infection (SARS-CoV-2) pandemic, differential diagnosis and treatment of viral pneumonia has become a rather urgent problem in medicine. Currently, new diagnostic methods are being developed and existing ones are being improved. Despite the variety of methods developed, the leading one is the polymerase chain reaction (PCR) which has been researched to have disadvantages. They include high cost of equipment, technical training of personnel, obtaining false negative results, and the complexity of research.
Bibliography:
1. Chuchalin AG, Sinopalnikov Al, Kozlov RS, et al. Community-acquired pneumonia in adults. Practical recommendations for diagnosis, treatment and prevention: manual for doctors. Clinical Microbiology and antimicrobial chemotherapy 2010; (12): 186-225.
2. Sinopalnikov Al, Kozlov RS. Community-acquired respiratory tract infections: a guide for doctors: a textbook for the system of postgraduate professional education of doctors. Moscow: Premier MT: Nash Gorod 2007; 353 p.
3. Torres A, Blasi F, Peetermans WE, et al. The aetiology and antibiotic management of community-acquired pneumonia in
adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis 2014; 33 (7): 1065-79. DOI: 10.1007/s10096-014-2067-1. PMID: 24532008; PMCID: PMC4042014.
4. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50 (2): 202-9. DOI: 10.1086/648678. PMID: 20014950; PMCID: PMC7107844.
5. Rachina SA, Kozlov RS, Shal EP, et al. A spectrum of causative bacterial pathogens in community-acquired pneumonia in multidisciplinary hospitals of Smolensk. Pulmonol 2011; (1): 5-18. DOI: 10.18093/0869-0189-2011-0-1-5-18.
6. Rachina SA, Zakharenkov IA, Dekhnich NN, et al. Etiology of severe community-acquired pneumonia in adults in the Russian Federation: preliminary results of a multicenter Sepia study. Molecular diagnostics — 2017: Proceedings of the IX all-Russian scientific and practical conference with international participation. Moscow, 2017; 256-7.
7. Starshinova АА, Kushnareva ЕА, Malkova AM, et al. New coronaviral infection: features of clinical course, capabilities of diagnostics, treatment and prevention in adults and children. Questions of modern Pediatrics 2020; (19): 123-31.
8. Guan WJ, Ni ZY, Ни Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; (18): 1708-20. DOI: 10.1056/NEJMoa2002032. PMID: 32109013; PMCID: PMC7092819.
9. Zheleznova AD, BufetovaAM. Diagnosis of coronavirus infection. Medical education today 2020; 3 (11): 140-9.
10. Pavia AT Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis 2011; (52): 284-9. DOI: 10.1093/cid/cir043. PMID: 21460286; PMCID: PMC3106235.
11. Miller WTJr, MickusTJ, Barbosa E Jr, et al. CT of viral lower respiratory tract infections in adults: comparison among viral organisms and between viral and bacterial infections. AJR Am J Roentgenol 2011; (5): 1088-95.
12. Rafat C, Klouche K, Ricard JD, et al. Severe Measles Infection: The Spectrum of Disease in 36 Critically III Adult Patients. Medicine (Baltimore) 2013; (5): 257-72. DOI: 10.1097/MD. 0b013e3182a713c2. PMID: 23982057; PMCID: PMC4553975.
13. Ooi GC, Khong PL, Muller NL, et al. Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients. Radiology 2004; 230 (3): 836-44. DOI: 10.1148/radiol. 2303030853. PMID: 14990845.
14. Ajlan AM, Ahyad RA, Jamjoom LG, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR Am J Roentgenol 2014; (4): 782-7. DOI: 10.2214/AJR. 14.13021. PMID: 24918624.
15. Das KM, Lee EY, Al Jawder SE, et al. Acute Middle East Respiratory Syndrome Coronavirus: Temporal Lung Changes Observed on the Chest Radiographs of 55 Patients. AJR Am J Roentgenol 2015; (3): 267-74. DOI: 10.2214/AJR. 15.14445. PMID: 26102309.
16. Choi WJ, Lee KN, Kang EJ, Lee H. Middle East Respiratory Syndrome-Coronavirus Infection: A Case Report of Serial Computed Tomographic Findings in a Young Male Patient. Korean J Radiol 2016; (1): 166-70. DOI: 10.3348/kjr. 2016.17.1.166. PMID: 26798230; PMCID: PMC4720805.
17. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-
analysis. J Med Virol 2020; (6): 577-83. DOI: 10.1002/jmv. 25757. PMID: 32162702; PMCID: PMC7228329.
18. Ternovoy SK, Serova NS, Belyaev AS, et al. COVID-19: first results of radiology in response to a new challenge. REJR 2020; 10 (1): 8-15. DOI: 10.21569/2222-7415-2020-10-1-8-15.
19. Tamayose М, Fujita J, Parrott G, et al. Correlations between extent of X-ray infiltration and levels of serum C-reactive protein in adult non-severe community-acquired pneumonia. J Infect Chemother 2015; (6): 456-63. DOI: 10.1016/j.jiac. 2015.02.009. PMID: 25817351.
20. Schuetz P, Litke A, Albrich WC, et al. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013; (2): 159-67. DOI: 10.1097/QCO.0b013e32835d0bec. PMID: 23434895.
21. Bruns AH, Oosterheert JJ, Hak E, et al. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008; (3): 726-32. DOI: 10.1183/09031936.00003608. PMID: 18508833.
22. NouvenneA, TicinesiA, Folesani G, etal. The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study. ВМС Geriatr 2016; (16): 16. DOI: 10.1186/s12877-016-0192-7. PMID: 26772604; PMCID: PMC4715290.
23. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121 (3): 219-25. DOI: 10.1016/j.amjmed.2007.10.033. PMID: 18328306.
24. Nseir W, Farah R, Mograbi J, et al. Impact of serum C-reactive protein measurements in the first 2 days on the 30-day mortality in hospitalized patients with severe community-acquired pneumonia: a cohort study. J Crit Care 2013; (28): 291-5.
25. Paiva MB, Botoni FA, Teixeira AL Jr, et al. The behavior and diagnostic utility of procalcitonin and five other inflammatory molecules in critically ill patients with respiratory distress and suspected 2009 influenza a H1N1 infection. Clinics (Sao Paulo) 2012; 67 (4): 327-34. DOI: 10.6061/clinics/2012(04)05. PMID: 22522757; PMCID: PMC3317251.
26. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; (5): 2620-29. DOI: 10.1172/JCI137244. PMID: 32217835; PMCID: PMC7190990.
27. Li Q, Ding X, Xia G, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. E Clinical Medicine 2020; (23): 100375. DOI: 10.1016/j.eclinm.2020.100375. PMID: 32368728; PMCID: PMC7196382.
28. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mai Infect 2020; (4): 332-4. DOI: 10.1016/j. medmal.2020.03.007. PMID: 32243911; PMCID: PMC7146693.
29. Bazdyrev ED. Coronavirus disease: a global problem of the 21st century. Complex problems of cardiovascular diseases 2020; 9 (2): 6-16. DOI: 10.17802/2306-1278-2020-9-2-6-16; ISSN: 2306-1278e ISSN: 2587-9537.
30. Menendez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; (11): 987-92. DOI: 10.1136/thx.2009.118612. PMID: 19762338.
31. Hu R, Han C, Pei S, et al. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents 2020; (2): 106051. DOI: 10.1016/j.ijantimicag. 2020.106051. PMID: 32534186; PMCID: PMC7286278.
32. Nikiforov VV, Suranova TG, ChernobrovkinaTYa, et al. New coronavirus infection (covid-19): clinical and epidemiological
aspects. Archive of internal medicine 2020; 87-93; ISSN: 2226-6704e ISSN: 2411-6564.
33. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. Thromb Haemost 2020; (5): 876-8. DOI: 10.1055/S-0040-1709650. PMID: 32246450; PMCID: PMC7295300.
34. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; (5): 475-81. DOI: 10.1016/S2213-2600 (20) 30079-5. Erratum in: Lancet Respir Med 2020 Apr; 8 (4): e26. PMID: 32105632; PMCID: PMC7102538.
35. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; (5): 846-8. DOI: 10.1007/s00134-020-05991-x. Erratum in: Intensive Care Med 2020; 46 (6): 1294-7. PMID: 32125452; PMCID: PMC7080116.
36. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; (10223): 507-13. DOI: 10.1016/S0140-6736(20)30211-7. PMID: 32007143; PMCID: PMC7135076.
37. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol 2020; (127): 104370. DOI: 10.1016/j.jcv.2020.104370. PMID: 32344321; PMCID: PMC7194648.
38. Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 2020; (6): 389-99. DOI: 10.1080/10408363.2020.1770 685. PMID: 32503382; PMCID: PMC7284147.
39. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; (1): 42-8. DOI: 10.1136/thx.2006.075077. PMID: 17573440.
40. Devyatkin AV, Devyatkin AA. A novel coronavirus infection — COVID-19. Origin, tropism, transmission routes, lab diagnostics and specific care The Kremlin medicine. Clinical Bulletin 2020; (2): 5-13.
41. Prilutskii AS. Coronavirus disease 2019. part 2: clinic, diagnosis, treatment and prevention. Bulletin of hygiene and epidemiology 2020; (24): 87-101.
42. Zaitsev AA. Acute respiratory viral infections: topical issues of diagnosis, treatment and prevention. Moscow: Aikonmed, 2017; 34 p.; ISBN 978-5-9908797-1-3.
43. Bevova MR, Netesov SV, Aulchenko YuS. New coronavirus infection COVID-19. Molecular genetics, Microbiology, and Virology 2020; (2): 51-8.
44. Nascimento MS, Souza AV, Ferreira AV, et al. High rate of viral identification and coinfections in infants with acute bronchiolitis. Clinics (Sao Paulo) 2010; (11): 1133-7. DOI: 10.1590/sl 807-59322010001100014. PMID: 21243286; PMCID: PMC2999709.
Attachment | Size |
---|---|
2021_01_013-018.pdf | 337.06 KB |